RPL30P6: A Promising Drug Target / Biomarker (G100270980)

Target Name: RPL30P6

NCBI ID: G100270980

RPL30P6

Other Name(s): Ribosomal protein L30 pseudogene 6 | ribosomal protein L30 pseudogene 6 | RPL30_4_501

RPL30P6: A Promising Drug Target / Biomarker

The protein RPL30P6 is a key regulator of the Replication Processivity of Retinal Proteins (RPL) in the retina. It is a member of the RPL family of proteins that play a crucial role in maintaining the integrity of the retina by regulating the movement of proteins into the retina. Mutations in the RPL30P6 gene have been linked to a range of disorders, including blindness, cataracts, and age-related macular degeneration. As a result, understanding the function of RPL30P6 and its potential as a drug target is of great interest.

Structure and Function

The RPL30P6 protein is a 21 kDa protein that is expressed in the retina, but also found in other tissues. It has a molecular weight of 21 kDa and a calculated pI of 9.95. The protein has a single transmembrane domain and a N-terminal intracellular tail. It plays a critical role in regulating the replication processivity of retinal proteins by ensuring that they are properly targeted to the retina.

RPL30P6 is a key regulator of the Replication Processivity of Retinal Proteins (RPL)

The RPL30P6 protein is a key regulator of the replication processivity of retinal proteins. It does this by ensuring that the protein responsible for the replication of the protein RPL30 is properly targeted to the retina. RPL30 is a 21 kDa protein that is involved in the regulation of the trafficking of proteins to the retina. It contains a C-terminal transmembrane domain and a N-terminal intracellular tail.

The RPL30P6 protein is involved in the regulation of the trafficking of RPL30 to the retina

The RPL30P6 protein is involved in the regulation of the trafficking of RPL30 to the retina. It does this by ensuring that RPL30 is properly processed and then targeted to the retina. RPL30 is a 21 kDa protein that is involved in the regulation of the trafficking of proteins to the retina. It contains a C-terminal transmembrane domain and a N-terminal intracellular tail.

The RPL30P6 protein is involved in the regulation of the processing and targeting of RPL30

The RPL30P6 protein is involved in the regulation of the processing and targeting of RPL30. It does this by ensuring that RPL30 is properly processed and then targeted to the retina. RPL30 is a 21 kDa protein that is involved in the regulation of the trafficking of proteins to the retina. It contains a C-terminal transmembrane domain and a N-terminal intracellular tail.

The RPL30P6 protein is involved in the regulation of the stability of RPL30 in the retina

The RPL30P6 protein is involved in the regulation of the stability of RPL30 in the retina. It does this by ensuring that RPL30 is properly retained in the retina and is not degraded. RPL30 is a 21 kDa protein that is involved in the regulation of the trafficking of proteins to the retina. It contains a C-terminal transmembrane domain and a N-terminal intracellular tail.

Mutations in the RPL30P6 gene have been linked to a range of disorders

Mutations in the RPL30P6 gene have been linked to a range of disorders, including blindness, cataracts, and age-related macular degeneration. It is important to understand the function of RPL30P6 and its potential as a drug target in order to develop new treatments for these disorders.

Conclusion

In conclusion, the RPL30P6 protein is a key regulator of the replication processivity of retinal proteins. It plays a crucial role in ensuring that the protein responsible for the replication of the protein RPL30 is properly targeted to the retina. Mutations in the RPL30P6 gene have been linked to a range of disorders, including blindness, cataracts, and age-related macular degeneration. As a result, understanding the function of RPL30P6 and its potential as a drug target is of great interest.

Protein Name: Ribosomal Protein L30 Pseudogene 6

The "RPL30P6 Target / Biomarker Review Report" is a customizable review of hundreds up to thousends of related scientific research literature by AI technology, covering specific information about RPL30P6 comprehensively, including but not limited to:
•   general information;
•   protein structure and compound binding;
•   protein biological mechanisms;
•   its importance;
•   the target screening and validation;
•   expression level;
•   disease relevance;
•   drug resistance;
•   related combination drugs;
•   pharmacochemistry experiments;
•   related patent analysis;
•   advantages and risks of development, etc.
The report is helpful for project application, drug molecule design, research progress updates, publication of research papers, patent applications, etc. If you are interested to get a full version of this report, please feel free to contact us at BD@silexon.ai

More Common Targets